TAT senior science writer Sharon Begley and national biotech columnist Adam Feuerstein tell us what CRISPR is (and is not), what other genome-editing methods are already being tested, and which companies are betting on these technologies to one day treat, cure, or prevent disease.

This is the year when CRISPR will move out of the lab and into patients in the first U.S. clinical trials of the genome-editing technology. See what Sharon, Adam, and webinar participants think success might look like.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • I attended the webinar on CRISPR, and found it very interesting. I would love to you have that webinar open to the public as it helped me (a 40 your veteran nurse understand this new technology). I would love to share it with my colleagues so they can also understand CRISPR as it roles out to the broader healthcare industry.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.